In the roughly six months since the Food & Drug Administration gave its blessing to the marketing of flibanserin, a prescription treatment for low libido in premenopausal women, the average patient taking the newly minted medication should have had three additional satisfying sexual events.
She...
from L.A. Times - Science http://ift.tt/1L1PRhi
via IFTTT
No comments:
Post a Comment